Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study

BMC Psychiatry volume 22, Article number: 777 (2022) Cite this article

Abstract

Objective

To explore the role of chronic inflammation in rheumatoid arthritis (RA) on cognition.

Methods and analysis

Six hundred sixty-one men and women aged ≥55 years who fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA were recruited from three healthcare trusts in the United Kingdom (UK) between May 2018 and March 2020. Study participants took part in interviews which captured sociodemographic information, followed by an assessment of cognition. RA specific clinical characteristics were obtained from hospital medical records. Participants were cognitively assessed using the Montreal Cognitive Assessment (MoCA) and were classified as cognitively impaired if they scored ≤27/30 points. Linear regression analyses were conducted to identify which demographic and clinical variables were potential predictors of cognitive impairment.

Results

The average age of participants was 67.6 years and 67% (444/661) were women. 72% (458/634; 95% CI 0.69 to 0.76) of participants were classified as cognitively impaired (MoCA≤27). Greater cognitive impairment was associated with older age (p = .006), being male (p = .041) and higher disease activity score (DAS28) (with moderate (DAS28 > 3.1) (p = 0.008) and high (DAS28 > 5.1) (p = 0.008)) compared to those in remission (DAS28 ≤ 2.6). There was no association between MoCA score and education, disease duration, RF status, anti-cyclic citrullinated peptide (anti-CCP) status, RA medication type or use of glucocorticoids or non-steroidal anti-inflammatory drugs (p > 0.05).

Conclusion

This study suggests that cognitive impairment is highly prevalent in older adults with RA. This impairment appears to be associated with higher RA disease activity and supports the concept that chronic systemic inflammation might accelerate cognitive decline. This underlines the importance of controlling the inflammatory response.

Peer Review reports

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting approximately 0.5–1% of the global population but is more common in women [1, 2]. The main characteristic of RA is persistent inflammation in the joint synovium [3]. Without early and effective management, RA can cause progressive joint damage resulting in reduced functional capacity and quality of life [4,5,6]. Disease Modifying Anti-Rheumatic Drugs (DMARDs) are used to reduce disease activity and joint destruction. Different types of DMARDs exist including conventional synthetic (cs) DMARDs, biologic (b) DMARDs and targeted synthetic (ts) DMARDs [7, 8]. RA is also associated with damage as a result of chronic systemic inflammation. This includes accelerated cardiovascular disease and stroke [9,10,11]. As a result, RA appears to be an ideal disease to study biologically to understand the accelerating effects of inflammation in a number of disease areas, including cognitive decline associated with dementia [12].

In recent years there has been increasing interest in the potential role of systemic inflammation in the pathogenesis of Alzheimer’s disease (AD) [13, 14]. This is of particular relevance in RA as these patients have higher levels of systemic inflammation than the general population, therefore, if AD is driven by inflammatory processes then these patients may be at an increased risk of cognitive impairment and dementia as has been suggested by recent epidemiological studies [15,16,17,18]. There are several small studies that have highlighted the burden of cognitive impairment in RA [19,20,21,22]. A systematic review sought to explore the prevalence of cognitive impairment in RA and found that individuals with RA significantly underperform in cognitive assessments compared to healthy controls and also identified age, education, disease activity and depression as factors associated with cognitive impairment, although this was inconsistent across individual studies and based on small sample sizes ranging from 13 to 157 participants [23].

As intact cognitive function in RA is also essential for successfully performing day-to-day activities and adhering to treatment programs, understanding the biological and clinical factors which may affect cognition in this condition is important for improving clinical outcomes and quality of life [24]. The purpose of this study was to investigate the prevalence of cognitive impairment in a larger population of older UK individuals with RA and identify specific factors that may be associated with cognitive impairment.

Methods

Sample and setting

Participants were recruited on behalf of the rheumatoid arthritis medication and memory study (RESIST), a multicentre longitudinal observational study which aims to compare cognitive decline in adults with both RA and mild cognitive impairment (MCI) who are on conventional synthetic disease modifying antirheumatic drugs (csDMARDs) to adults with both RA and MCI who are on a Tumour Necrosis Factor Inhibitor (TNFi). The primary objective is to determine if TNFi treatment reduces the rate of cognitive decline compared to csDMARDs in patients with RA and MCI. Results from the longitudinal study will be important in further describing the role of inflammation in the pathogenesis of AD and will help to determine the potential of TNFi in prevention of cognitive decline. All data presented here was collected during baseline screening interviews, prior to enrolment on the longitudinal phase of the study. We used the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) cross sectional checklist when writing our report [25].

Participants were recruited between May 2018 and March 2020 during their regularly scheduled check-up appointments in rheumatology outpatient clinics within the Belfast Health and Social Care Trust (BHSCT) located in the Royal Victoria Hospital, Belfast City Hospital, and Musgrave Park Hospital; Northern Health and Social Care Trust (NHSCT) located in Antrim Area Hospital; and University Hospital Southampton NHS Foundation Trust (UHS) located in Southampton General Hospital.

All individuals older than 54 years of age who fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA [26] (regardless of disease duration) were identified and approached for inclusion in the study by rheumatology consultants and specialist rheumatology nurses.

Study procedures

Participants took part in face-to-face interviews with trained research members after providing written informed consent. Interviews captured sociodemographic information including age, sex and education. Disease related characteristics, including a disease activity score for RA (DAS28) upon commencement of treatment, were obtained from medical records where available. Participants indicated the date (or approximate date) of their RA diagnosis, which was used to calculate a measure of disease duration (in years). This was confirmed in clinical records, if available.

DAS28 calculates a score based on the number of tender and swollen joints, a visual analogue scale global assessment of health, and acute phase reactants – either erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) titre level [27]. In the present study DAS28-ESR was used. Disease activity was categorised based on the following scores: remission (< 2.6), low activity (2.6–3.2), moderate activity (3.2–5.1), or high activity (> 5.1) [28].

Anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) are autoantibodies associated with RA and were also investigated as a measure of seropositivity.

Participants were classified as taking either a csDMARD, a TNFi, or a combination of both. Participants also provided a list of any other medication they were currently taking. From this information, two additional variables were computed: glucocorticoid use (specifically use of prednisolone; participants were classified as either taking or not taking) and non-steroidal anti-inflammatory drug (NSAID) use (participants were classified as taking or not taking any of the following; aspirin, diclofenac, ibuprofen or naproxen).

Participants were cognitively assessed using the Montreal Cognitive Assessment (MoCA) (Version 7.1). The MoCA was developed as a screening tool for the detection of MCI and has been widely validated for use in both clinical and research settings [29,30,31,32,33]. It is a 10-min, 30-point pen and paper test which assesses multiple cognitive domains including visuospatial skills, executive function, language, memory (delayed recall), attention, concentration, abstraction, and orientation. To account for differences in educational attainment an additional one point was awarded if the subject had spent ≤12 years in full-time education. Cognitive impairment was defined by a cut-off score of ≤27/30 pts. which has previously demonstrated good sensitivity for detection of MCI [34, 35].

Statistics

Participant characteristics were summarised using means and standard deviations (SD) for continuous variables and relative frequencies and percentages for categorical variables. The proportion of participants with cognitive impairment was determined and a linear regression model was created to identify variables associated with MoCA score. The model included variables which have been previously linked with cognitive impairment in the context of RA including age, sex, education (≤12 years or > 12 years), disease duration, disease activity (remission, low, moderate, or high), RF status (positive or negative), anti-CCP status (positive or negative), RA medication type, and use of glucocorticoids and NSAIDs.

Linear regression was used to avoid information and power loss associated with dichotomising the continuous variable of MoCA score into the categories of cognitively impaired/non-impaired. However, for consistency, we also conducted logistic regression using the same predictors to examine whether they were associated with the likelihood of a participant being classified as impaired (MoCA ≤27/30).

It is likely that other confounding variables that were not collected at the screening stage would also have an influence on cognitive function (e.g. pain, depression, physical impairment). Data on these variables was collected later during the longitudinal phase of the study and hence could not be included in baseline analyses. All analyses were conducted using SPSS, version 27.0.

Patient and public involvement

Members of the public were involved in the design and preparation of the RESIST study proposal, specifically in wording and logistics. We also received advice when designing study documents including the participant information sheet, consent forms, and protocol. Research Network volunteers from the Alzheimer’s Society assigned to the project were invited into the project advisory committee and advised on all aspects of the project.

Results

A total of 720 participants were interviewed between the 22nd May 2018 and the 10th March 2020. N = 59 participants were excluded as they did not meet inclusion criteria (n = 54 participants were not on a csDMARD or TNFi, n = 3 participants did not have a diagnosis of RA, n = 1 participant was under 55 years old, and n = 1 participant had an incomplete MoCA). Therefore 661 participants were included in this analysis. Participant sociodemographic and clinical characteristics are presented in Table 1. The mean age of participants was 67.6 years (SD 8.1), 67% were women and 37% had > 12 schooling years. RA clinical characteristics were obtained from medical records and thus were not always available. Data on disease duration was available for n = 556 participants, DAS28 score was available for n = 337 participants, RF status was available for n = 437 and anti-CCP status was available for n = 423. Five hundred ninety-two participants provided information on any medication they were taking at the time of screening.

Table 1 Summary of participant demographic and clinical characteristics (n = 661)a
Full size table

Education-adjusted MoCA score was available for n = 634 participants at the time of analysis. The mean education-adjusted MoCA score was 25.4 (SD 3.1). The proportion of participants who were classified as cognitively impaired according to a cut off of ≤27/30 was 72.2% (458/634; 95% CI 0.69 to 0.76). Those who were cognitively impaired, on average were older (68.8 years versus 64.7 years), had higher ESR measurements (23.7 mm/hr. versus 17.1 mm/hr), higher DAS28 scores (3.6 versus 3.1) and were more likely to have spent 12 years or less in full-time education (66.8% versus 46.2%). Disease duration did not significantly differ between those who were classified as cognitively impaired and those who were not.

A MoCA cut-off score of < 26/30 is also widely used for detection of MCI, demonstrating good sensitivity and specificity [32,33,34,35,36]. For comparison, when we used this cut-off score, 45.7% (290/634; 95% CI 0.42 to 0.50) of our population was classified as cognitively impaired. However, we elected to use a cut-off of ≤27/30 in all of our analyses as participants in the present sample were aged just 55 years and older (mean 67.6 years) and were not recruited from memory clinics.

The associations between MoCA score and various characteristics are presented in Table 2. A multivariable regression model with age, sex, education, RA disease activity, RF status, anti-CCP status, RA medication type, glucocorticoid (prednisolone) use and NSAID use as independent variables explained 23% of the variance in MoCA score (F(13, 202) = 4.57, p < .001, R2 = 0.23, adjusted R2 = 0.18). Linear regression analysis revealed that increasing age (p = .006) was associated with lower MoCA score. After controlling for the other variables in the model, per 10-year increase in age, MoCA was on average 0.58 (95% CI 0.17, 1.00) points lower. Sex was also associated with MoCA score, with females scoring 0.74 (95% CI 0.03, 1.45) points higher than males.

Table 2 Summary of linear regression analyses with MoCA score as the outcome
Full size table

On linear regression, participants with moderate (p = .008) and high (p = .008) levels of disease activity had lower MoCA scores by on average 1.10 units (95% CI 0.30, 1.90) and 1.41 units (95% CI 0.36, 2.45), respectively, compared with those in remission after adjustments. Low disease activity did not appear to affect cognition compared to those in remission (p = .275). Neither RF nor anti-CCP status was associated with cognition after adjustment for other variables in the model (ps > .05). RA medication was not associated with MoCA score; those taking both a csDMARD and a TNFi did not show significant differences in score compared to those taking csDMARDs only (p = .601) or those taking TNFis only (p = .387). Neither prednisolone use nor NSAID use was associated with MoCA score (ps > .05). Age, disease severity and NSAID use were significantly associated with the likelihood of participants being classified as cognitively impaired (MoCA ≤27/30) in a logistic regression model (see Additional file 1).

Discussion

This study produced descriptive data for a large sample of older adults with RA that were cognitively assessed using the MoCA and investigated the prevalence and potential predictors of cognitive impairment in this population. Over two thirds (72.2%) of our participants were classified as cognitively impaired using a MoCA cut-off score of ≤27/30 points.

Our findings are analogous to previous studies which assessed cognitive function in patients with RA. A study by Bartolini et al. [20] reported cognitive impairment in 38–71% of their RA cohort with worst cognitive outcomes observed in the visuospatial/executive function tasks. A study by Shin et al. [21] observed that cognitive impairment in RA ranged from 8% on semantic fluency tasks to 29% on visuospatial/memory tasks with 31% of their cohort being classified as cognitively impaired overall. Similarly, Appenzeller et al. [19] found 30% of their RA cohort to be cognitively impaired in a battery of neuropsychological assessments. We found lower prevalence rates compared to a recent study by Vitturi et al. [22] who observed cognitive impairment in 98% of their RA population using a cut-off score of 26/30 in the MoCA. This discrepancy may be due to low educational attainment in that study as 46% of RA participants had less than 4 schooling years and 3% were illiterate. The main limitation of these studies is that they consisted of small RA sample sizes [19, 20, 22]. While methodology varies between these studies making direct comparisons difficult, they imply that the burden of cognitive impairment in RA is significant and highlights the need for standardised longitudinal assessment of cognition in these patients.

In this study, age was identified as a non-modifiable demographic factor that was associated with cognitive impairment. Age is known to be the biggest risk factor for AD and has been negatively correlated with MoCA performance in many previous studies, thus this result was anticipated [36,37,38,39,40,41].

We demonstrated an inverse linear relationship between DAS28 score and MoCA score which is analogous to previous studies [42, 43]. Moreover, we found that moderate and high disease activity were associated with worse cognitive outcomes compared to those in remission. Together, these findings support the hypothesis that higher levels of chronic systemic inflammation significantly affect cognitive function [44, 45] which has implications beyond the scope of RA. Thus strategies to prevent cognitive impairment and reduce risk of AD should include measures to modulate inflammation.

It has been hypothesised that anti-inflammatory drugs often prescribed for RA may be beneficial in slowing or preventing cognitive decline [12]. Those taking NSAIDs in the present study were less likely to be classified as cognitively impaired in a logistic regression model. Although results from initial observational studies suggested that NSAID use was associated with a reduced risk of dementia [46,47,48], there has been little evidence of cognitive benefit in subsequent clinical trials [49,50,51,52,53]. There are now several studies which have suggested the potential benefits of DMARDs on cognition [16, 18, 54,55,56,57], but this requires further investigation in longitudinal studies.

This study identified several limitations that should be taken into consideration when interpreting the results. This study was cross-sectional and as such cannot imply a cause-effect relationship between variables and cognitive outcome. Additionally, no control group was included in the study design, therefore prevalence of cognitive impairment in RA could not be compared to a healthy population or other clinical group. As noted in the introduction, however, a recent systematic review found that individuals with RA significantly underperform in cognitive assessments compared to healthy controls [23]. Cognitive function was assessed using the MoCA alone and the sensitivity and specificity of the cut-off score used was not able to be evaluated due to the lack of known MCI diagnoses. Therefore, the possibility of false positives cannot be dismissed and will be further investigated in the longitudinal RESIST study. We did not record domain level scores from the MoCA. It is possible that inflammation may have stronger associations with performance in specific cognitive domains such as memory or processing speed; future studies should investigate this possibility further by including domain specific measures of cognitive function. As part of the eligibility criteria for the RESIST study, only participants who were on a csDMARD or TNFi at the time of enrolment were considered in this analysis which may limit the generalisability of our findings. Additionally, there was a large amount of missing data in relation to RA disease characteristics and so regression analyses were conducted on a reduced sample which may not be representative of the entire study population. While this study included several potential confounding variables it did not include concurrently measured information on comorbidities (e.g. cardiovascular disease [58,59,60]), neuropsychological conditions (e.g. depression/anxiety [60,61,62]) or other RA disease features (pain [62, 63], fatigue [64], medication [65, 66]) which may influence cognitive function. This information is collected within the longitudinal RESIST study that is ongoing. Results from RESIST will provide more clarity on the association between inflammation, comorbidities and cognition.

Despite limitations this study has strengths and important implications. This is the largest study to date to investigate cognitive function in a population of adults with RA, thus adding valuable information to the existing evidence base surrounding the prevalence of cognitive impairment in these patients. Cognitive impairment in RA can have significant impact on ability to plan and successfully complete daily activities and is also important for adhering to treatment regimens. This study suggests that routine cognitive screening in rheumatology clinics may be a useful tool in RA disease management. Additionally, higher levels of disease activity were associated with poorer cognitive performance, suggesting that the association between reduced cognitive function may be, at least in part, driven by the effects of systemic inflammation. This raises the intriguing possibility that controlling the systemic inflammatory response in RA using DMARDs might have benefits to cognitive function. This could also be transferable to other situations in which inflammation appears to drive cognitive decline such as AD.

Conclusions

In this study, which is the largest to date that has investigated cognition in RA, we found that cognitive impairment was highly prevalent in RA and is partly driven by the effects of chronic systemic inflammation. This has implications for our understanding of how chronic inflammation may drive accelerated cognitive decline in the general population. RA disease activity is a potentially modifiable risk factor that may be targeted to slow or prevent cognitive decline.

Availability of data and materials

Non-identifiable relevant raw data on which the conclusions of this paper rely is supplied as an Excel file in Supplementary material.

Abbreviations

RA:

Rheumatoid arthritis

ACR/EULAR:

American College of Rheumatology/European League Against Rheumatism

UK:

United Kingdom

MoCA:

Montreal Cognitive Assessment

DAS28:

Disease activity score

anti-CCP:

Anti-cyclic citrullinated peptide

DMARDs:

Disease Modifying Anti-Rheumatic Drugs

cs DMARDs:

Conventional synthetic Disease Modifying Anti-Rheumatic Drugs

b DMARDs:

Biologic Disease Modifying Anti-Rheumatic Drugs

ts DMARDs:

Targeted synthetic Disease Modifying Anti-Rheumatic Drugs

AD:

Alzheimer’s disease

RESIST:

Rheumatoid arthritis medication and memory study

MCI:

Mild cognitive impairment

TNFi:

Tumour Necrosis Factor Inhibitor

STROBE:

Strengthening the Reporting of Observational Studies in Epidemiology

BHSCT:

Belfast Health and Social Care Trust

NHSCT:

Northern Health and Social Care Trust

UHS:

University Hospital Southampton NHS Foundation Trust

ESR:

Erythrocyte sedimentation rate

CRP:

C-reactive protein

RF:

Rheumatoid factor

NSAID:

Non-steroidal anti-inflammatory drug

SD:

Standard deviation

References

  1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–8. https://doi.org/10.1016/j.semarthrit.2006.08.006.

    Article  Google Scholar 

  2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):1–6. https://doi.org/10.1186/ar2669.

    Article  Google Scholar 

  3. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27:S18–24. https://doi.org/10.1016/S0720-048X(98)00038-2.

    Article  Google Scholar 

  4. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000;39(2):122–32. https://doi.org/10.1093/rheumatology/39.2.122.

    Article  CAS  Google Scholar 

  5. Uhlig T, Loge JH, Kristiansen IS, Kvien TK. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241–7 pmid:17516624.

    Google Scholar 

  6. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–94. https://doi.org/10.1002/art.1780370408.

    Article  CAS  Google Scholar 

  7. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. https://doi.org/10.1136/annrheumdis-2013-204573.

    Article  CAS  Google Scholar 

  8. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4(3):130–6. https://doi.org/10.1016/j.autrev.2004.09.002.

    Article  Google Scholar 

  9. Södergren A, Stegmayr B, Lundberg V, Öhman ML, Wållberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):263–6. https://doi.org/10.1136/ard.2006.052456.

    Article  Google Scholar 

  10. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ. 2012;8:344. https://doi.org/10.1136/bmj.e1257.

    Article  Google Scholar 

  11. Meune C, Touzé E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103(4):253–61. https://doi.org/10.1016/j.acvd.2010.03.007.

    Article  Google Scholar 

  12. Mason A, Holmes C, Edwards CJ. Inflammation and dementia: using rheumatoid arthritis as a model to develop treatments? Autoimmun Rev. 2018;17(9):919–25. https://doi.org/10.1016/j.autrev.2018.04.001.

    Article  CAS  Google Scholar 

  13. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421. https://doi.org/10.1016/S0197-4580(00)00124-X.

    Article  CAS  Google Scholar 

  14. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia. 2013;61(1):71–90. https://doi.org/10.1002/glia.22350.

    Article  Google Scholar 

  15. Wallin K, Solomon A, Kåreholt I, Tuomilehto J, Soininen H, Kivipelto M. Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. J Alzheimers Dis. 2012;31(3):669–76. https://doi.org/10.3233/JAD-2012-111736.

    Article  Google Scholar 

  16. Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for rheumatoid arthritis and risk of Alzheimer’s disease: a nested case-control analysis. CNS Drugs. 2016;30(11):1111–20. https://doi.org/10.1007/s40263-016-0374-z.

    Article  CAS  Google Scholar 

  17. Ungprasert P, Wijarnpreecha K, Thongprayoon C. Rheumatoid arthritis and the risk of dementia: a systematic review and meta-analysis. Neurol India. 2016;64(1):56. https://doi.org/10.4103/0028-3886.173623.

    Article  Google Scholar 

  18. Zhou M, Xu R, Kaelber DC, Gurney ME. Tumor necrosis factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS One. 2020;15(3):e0229819. https://doi.org/10.1371/journal.pone.0229819.

    Article  CAS  Google Scholar 

  19. Appenzeller S, Bertolo MB, Costallat LT. Cognitive impairment in rheumatoid arthritis. Methods Find Exp Clin Pharmacol. 2004;26(5):339–44. https://doi.org/10.1358/mf.2004.26.5.831324.

    Article  CAS  Google Scholar 

  20. Bartolini M, Candela M, Brugni M, Catena L, Mari F, Pomponio G, et al. Are behaviour and motor performances of rheumatoid arthritis patients influenced by subclinical cognitive impairments? A clinical and neuroimaging study. Clin Exp Rheumatol. 2002;20(4):491–8 pmid:12175104.

    CAS  Google Scholar 

  21. Shin SY, Katz P, Wallhagen M, Julian L. Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res. 2012;64(8):1144–50. https://doi.org/10.1002/acr.21683.

    Article  Google Scholar 

  22. Vitturi BK, Nascimento BA, Alves BR, de Campos FS, Torigoe DY. Cognitive impairment in patients with rheumatoid arthritis. J Clin Neurosci. 2019;69:81–7. https://doi.org/10.1016/j.jocn.2019.08.027.

    Article  Google Scholar 

  23. Meade T, Manolios N, Cumming SR, Conaghan PG, Katz P. Cognitive impairment in rheumatoid arthritis: a systematic review. Arthritis Care Res. 2018;70(1):39–52. https://doi.org/10.1002/acr.23243.

    Article  Google Scholar 

  24. Abeare CA, Cohen JL, Axelrod BN, Leisen JC, Mosley-Williams A, Lumley MA. Pain, executive functioning, and affect in patients with rheumatoid arthritis. Clin J Pain. 2010;26(8):683 pmid:20862788.

    Article  Google Scholar 

  25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

  26. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584.

    Article  Google Scholar 

  27. Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Care Res. 2003;49(S5):S214–24. https://doi.org/10.1002/art.11407.

    Article  Google Scholar 

  28. Fransen J, Van Riel PL. DAS remission cut points. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-29 pmid:17083759.

    Google Scholar 

  29. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. https://doi.org/10.1111/j.1532-5415.2005.53221.x.

    Article  Google Scholar 

  30. Hobson J. The Montreal cognitive assessment (MoCA). Occup Med. 2015;65(9):764–5. https://doi.org/10.1093/occmed/kqv078.

    Article  Google Scholar 

  31. Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement. 2013;9(5):529–37. https://doi.org/10.1016/j.jalz.2012.10.001.

    Article  Google Scholar 

  32. Smith T, Gildeh N, Holmes C. The Montreal cognitive assessment: validity and utility in a memory clinic setting. Can J Psychiatr. 2007;52(5):329–32. https://doi.org/10.1177/070674370705200508.

    Article  Google Scholar 

  33. Freitas S, Simões MR, Alves L, Santana I. Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27(1):37–43. https://doi.org/10.1097/WAD.0b013e3182420bfe.

    Article  Google Scholar 

  34. Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, Lamy C, et al. Is the Montreal cognitive assessment superior to the Mini-mental state examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke. 2011;42(6):1712–6. https://doi.org/10.1161/STROKEAHA.110.606277.

    Article  Google Scholar 

  35. Ciesielska N, Sokołowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kędziora-Kornatowska K. Is the Montreal cognitive assessment (MoCA) test better suited than the Mini-mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol. 2016;50(5):1039–52. https://doi.org/10.12740/PP/45368.

    Article  Google Scholar 

  36. Kopecek M, Stepankova H, Lukavsky J, Ripova D, Nikolai T, Bezdicek O. Montreal cognitive assessment (MoCA): normative data for old and very old Czech adults. Appl Neuropsychol. 2017;24(1):23–9. https://doi.org/10.1080/23279095.2015.1065261.

    Article  Google Scholar 

  37. Apolinario D, Dos Santos MF, Sassaki E, Pegoraro F, Pedrini AV, Cestari B, et al. Normative data for the Montreal cognitive assessment (MoCA) and the memory index score (MoCA-MIS) in Brazil: adjusting the nonlinear effects of education with fractional polynomials. Int J Geriatr Psychiatry. 2018;33(7):893–9. https://doi.org/10.1002/gps.4866.

    Article  Google Scholar 

  38. Freitas S, Simões MR, Alves L, Santana I. Montreal cognitive assessment (MoCA): normative study for the Portuguese population. J Clin Exp Neuropsychol. 2011;33(9):989–96. https://doi.org/10.1080/13803395.2011.589374.

    Article  Google Scholar 

  39. Kenny RA, Coen RF, Frewen J, Donoghue OA, Cronin H, Savva GM. Normative values of cognitive and physical function in older adults: findings from the Irish longitudinal study on ageing. J Am Geriatr Soc. 2013;61:S279–90. https://doi.org/10.1111/jgs.12195.

    Article  Google Scholar 

  40. Malek-Ahmadi M, Powell JJ, Belden CM, O’Connor K, Evans L, Coon DW, et al. Age-and education-adjusted normative data for the Montreal cognitive assessment (MoCA) in older adults age 70–99. Aging Neuropsychol Cognit. 2015;22(6):755–61. https://doi.org/10.1080/13825585.2015.1041449.

    Article  Google Scholar 

  41. Narazaki K, Nofuji Y, Honda T, Matsuo E, Yonemoto K, Kumagai S. Normative data for the Montreal cognitive assessment in a Japanese community-dwelling older population. Neuroepidemiology. 2013;40(1):23–9. https://doi.org/10.1159/000339753.

    Article  Google Scholar 

  42. Katchamart W, Narongroeknawin P, Phutthinart N, Srinonprasert V, Muangpaisan W, Chaiamnauy S. Disease activity is associated with cognitive impairment in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38(7):1851–6. https://doi.org/10.1007/s10067-019-04488-3.

    Article  Google Scholar 

  43. Lee JH, Kim GT, Kim YK, Lee SG. Cognitive function of patients with rheumatoid arthritis is associated with disease activity but not carotid atherosclerotic changes. Clin Exp Rheumatol. 2018;36(5):856–61 pmid:29652660.

    Google Scholar 

  44. Sangha PS, Thakur M, Akhtar Z, Ramani S, Gyamfi RS. The Link Between Rheumatoid Arthritis and Dementia: A Review. Cureus. 2020;12(4). https://doi.org/10.7759/cureus.7855.

  45. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010;1207(1):155–62. https://doi.org/10.1111/j.1749-6632.2010.05726.x.

    Article  Google Scholar 

  46. Chang KH, Hsu YC, Hsu CC, Lin CL, Hsu CY, Lee CY, et al. Prolong exposure of NSAID in patients with RA will decrease the risk of dementia: a nationwide population-based cohort study. Medicine. 2016;95(10). https://doi.org/10.1097/md.0000000000003056.

  47. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–32. https://doi.org/10.1212/WNL.47.2.425.

    Article  CAS  Google Scholar 

  48. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc. 1998;73(10):951–5. Elsevier. https://doi.org/10.4065/73.10.951.

    Article  CAS  Google Scholar 

  49. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68(21):1800–8. https://doi.org/10.1212/01.wnl.0000260269.93245.d2.

    Article  CAS  Google Scholar 

  50. ADAPT Research Group. Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7):896. https://doi.org/10.1001/archneur.2008.65.7.nct70006.

    Article  Google Scholar 

  51. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819–26. https://doi.org/10.1001/jama.289.21.2819.

    Article  CAS  Google Scholar 

  52. Price JF, Stewart MC, Deary IJ, Murray GD, Sandercock P, Butcher I, et al. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ. 2008;337. https://doi.org/10.1136/bmj.a1198.

  53. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ. 2007;334(7601):987. https://doi.org/10.1136/bmj.39166.597836.BE.

    Article  CAS  Google Scholar 

  54. Judge A, Garriga C, Arden NK, Lovestone S, Prieto-Alhambra D, Cooper C, et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dementia (N Y). 2017;3(4):612–21. https://doi.org/10.1016/j.trci.2017.10.002.

    Article  Google Scholar 

  55. Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358(9280):455–60. https://doi.org/10.1016/S0140-6736(01)05623-9.

    Article  Google Scholar 

  56. McGuinness B, Holmes C, Mirakhur A, Kearsley-Fleet L, Vieira R, Watson K, et al. The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR-RA. Int J Geriatr Psychiatry. 2018;33(3):556–8. https://doi.org/10.1002/gps.4793.

    Article  Google Scholar 

  57. Butchart J, Brook L, Hopkins V, Teeling J, Püntener U, Culliford D, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161–8. https://doi.org/10.1212/WNL.0000000000001617.

    Article  CAS  Google Scholar 

  58. Hashimoto H, Kawamura M, Yukami T, Ishihara M, Bamba Y, Kaneshiro S, et al. Etiology of acute ischaemic cerebrovascular disease associated with rheumatoid arthritis: changes with progression of anti-inflammatory therapy. Eur J Neurol. 2018;25(12):1462–9. https://doi.org/10.1111/ene.13751.

    Article  CAS  Google Scholar 

  59. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–7. https://doi.org/10.1161/01.CIR.0000054612.26458.B2.

    Article  Google Scholar 

  60. Oláh C, Kardos Z, Andrejkovics M, Szarka E, Hodosi K, Domján A, et al. Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety. Rheumatol Int. 2020;40(4):529–40. https://doi.org/10.1007/s00296-019-04449-8.

    Article  CAS  Google Scholar 

  61. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013;52(12):2136–48. https://doi.org/10.1093/rheumatology/ket169.

    Article  Google Scholar 

  62. Brown SC, Glass JM, Park DC. The relationship of pain and depression to cognitive function in rheumatoid arthritis patients. Pain. 2002;96(3):279–84. https://doi.org/10.1016/S0304-3959(01)00457-2.

    Article  Google Scholar 

  63. Hart RP, Wade JB, Martelli MF. Cognitive impairment in patients with chronic pain: the significance of stress. Curr Pain Headache Rep. 2003;7(2):116–26. https://doi.org/10.1007/s11916-003-0021-5.

    Article  Google Scholar 

  64. Akdoğan S, Ayhan FF, Yıldırım Ş, Borman P. Impact of fatigue on cognitive functioning among premenopausal women with fibromyalgia syndrome and rheumatoid arthritis: the controlled study. J Musculoskelet Pain. 2013;21(2):135–46. https://doi.org/10.3109/10582452.2013.806977.

    Article  Google Scholar 

  65. Coluccia D, Wolf OT, Kollias S, Roozendaal B, Forster A, Dominique JF. Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. J Neurosci. 2008;28(13):3474–8. https://doi.org/10.1523/JNEUROSCI.4893-07.2008.

    Article  CAS  Google Scholar 

  66. Chou MH, Wang JY, Lin CL, Chung WS. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: a propensity score-matched case–control study. Toxicol Appl Pharmacol. 2017;334:217–22. https://doi.org/10.1016/j.taap.2017.09.014.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all participants for taking part in this study, as well as all doctors, nurses and psychologists within BHSCT, NHSCT, UHS, Southern Health Foundation NHS Trust and Northern Ireland Clinical Research Network (NICRN) who contributed to recruitment. We thank Dr. Lena Azbel-Jackson, Patricia Quinn, Michael McAlinden, Sylvia Clyde and Craig Woods for their ongoing contributions to data collection and collation. We also thank the research network volunteers assigned to the RESIST study: Gordon Kennedy, Bill Megraw and Kieran Hanna, for their contributions to the development and design of the study.

This work was submitted as part of Bethany McDowell’s PhD thesis ‘TNF inhibitors for the prevention of Alzheimer’s disease’.

School of Medicine, Dentistry and Biomedical Sciences.

Student thesis: Doctoral Thesis › Doctor of Philosophy.

https://pureadmin.qub.ac.uk/ws/portalfiles/portal/248082205/TNF_inhibitors_for_the_prevention_of_Alzheimer_s_disease.pdf

Funding

This study was supported by funding from the Alzheimer’s Society and Health and Social Care Research and Development Northern Ireland. Research network volunteers were involved in the design of the study proposal. The funders were not involved in the collection, analysis or interpretation of data, the writing of this manuscript or in the decision to submit this article for publication. Queen’s University Belfast agreed to act as sponsor for this study.

Author information

Authors and Affiliations

  1. Queen’s University Belfast, Belfast, Northern Ireland

    Bethany McDowell, Calum Marr, Christopher Cardwell & Bernadette McGuinness

  2. University of Southampton, Southampton, England

    Clive Holmes & Christopher J. Edwards

  3. Southern Health NHS Foundation Trust, Southampton, England

    Clive Holmes

  4. NIHR Southampton Clinical Research Facility, Southampton, England

    Christopher J. Edwards

  5. University Hospital Southampton NHS Foundation Trust, Southampton, England

    Christopher J. Edwards

  6. Belfast Health and Social Care Trust, Belfast, Northern Ireland

    Michelle McHenry

  7. Northern Health and Social Care Trust, Antrim, Northern Ireland

    Gary Meenagh

Authors
  1. Bethany McDowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Calum Marr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clive Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher J. Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher Cardwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michelle McHenry
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gary Meenagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernadette McGuinness
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BMcG, CH, CE, CC, MM and GM contributed to the design of this study. BMcD, CE, MM and GM contributed to recruitment of patients. BMcD contributed to data collection and data analysis. CM contributed to data analysis. All authors contributed to drafting the manuscript and approved the final version prior to submission. BMcD and BMcG are the guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Corresponding author

Correspondence to Bernadette McGuinness.

Ethics declarations

Ethics approval and consent to participate

The RESIST study was performed in accordance with the Declaration of Helsinki. The RESIST study was approved by the West Midlands – Black County Research Ethics Committee (REC reference: 17/WM/0161). Research governance permission was also granted by local research and development departments in both Northern Ireland (BHSCT, NHSCT) and Southampton (UHS). All patients provided written informed consent prior to recruitment.

Consent for publication

Not applicable. This manuscript does not include details, images, or videos relating to an individual person.

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare funding obtained from the Alzheimer’s Society and Health and Social Care Research and Development Northern Ireland. CE reports grants for research support from Abbvie, Biogen and Samsung for work that was not directly related to this research but was in the field of biological therapies. He was also paid consulting fees from Abbvie, GSK and Gilead for work that was not directly related to this research. CE discloses receiving payments from Abbvie, Pfizer, Biogen, Fresenius and Janssen for lectures/presentations in the last 3 years. MMcH reports receiving funding to attend conferences from a number of companies who produce anti-TNF medications over the last 3 years and discloses that registration fees were covered by UCB.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Binary logistic regression predicting likelihood of cognitive impairment (scoring ≤27 on MoCA).

Additional file 2.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McDowell, B., Marr, C., Holmes, C. et al. Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study. BMC Psychiatry 22, 777 (2022). https://doi.org/10.1186/s12888-022-04417-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12888-022-04417-w

Keywords

BMC Psychiatry

ISSN: 1471-244X

Contact us